News und Analysen

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen

Integra Resources (NYSEAMERICAN:ITRG) reported first-quarter 2026 results that management said reflected a deliberate reinvestment phase at its Florida Canyon mine, alongside continued permitting

• Viking Sails to All-Time Highs—Fundamentals Signal More to Come

Viking (NYSE:VIK) reported a stronger first quarter for fiscal 2026 and announced a leadership transition, with founder Torstein

NeoVolta (NASDAQ:NEOV) reported third-quarter fiscal 2026 revenue of approximately $2 million, roughly in line with the year-earlier period, while management emphasized progress on its transition

• 4 Reasons Pfizer Could Be a Value Play You Can't Miss

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for

ImmuCell (NASDAQ:ICCC) reported a record first quarter of 2026, with management saying the company’s narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever

MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute

Tamboran Resources (NYSE:TBN) said it remains on track to deliver first gas from its Beetaloo Basin pilot project in the third quarter of the calendar year, as the company highlighted farm-out

STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing

KinderCare Learning Companies (NYSE:KLC) reported modest first-quarter revenue growth while management said lower enrollment in its early childhood education centers continued to pressure

• 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease

• 2 Lesser-Known Photonics Firms May Play an Outsized Role in AI

Nova (NASDAQ:NVMI) reported record first-quarter 2026 revenue and profitability, with management citing strong demand from advanced

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in

• Best Agriculture Stocks to Buy in 2020

Bayer Aktiengesellschaft (ETR:BAYN) executives said the company’s Crop Science division remains on track with a five-year plan centered on cost savings

Aveanna Healthcare (NASDAQ:AVAH) raised its full-year 2026 outlook after reporting double-digit revenue and adjusted EBITDA growth in the first quarter, citing improved reimbursement rates, higher

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are

• High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the

Cellebrite DI (NASDAQ:CLBT) reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives

Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter

• Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026

Premier Foods (LON:PFD) said full-year trading profit rose ahead of its upgraded expectations, helped by stronger branded sales in the second half, market share gains and continued growth from its